Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7366 to 7380 of 7708 results

  1. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Technology appraisal guidance
    Published
    21 March 2018

  2. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Technology appraisal guidance
    Published
    27 March 2002

  3. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Evidence summary
    Published
    24 June 2019

  4. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    In development [GID-TA11163] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    In development [GID-TA11433] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued [GID-TA11041]

    Technology appraisal guidance
    Discontinued

  7. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued [GID-TA11026]

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued [GID-TA11000]

    Technology appraisal guidance
    Discontinued

  9. TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure (MIB298)

    This medtech innovation briefing has been replaced by NICE diagnostic guidance on heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices.

    Medtech innovation briefing
    Published
    31 May 2022

  10. Ventripoint Medical System Plus for measuring heart volume and function (MIB310)

    February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.

    Medtech innovation briefing
    Published
    1 November 2022

  11. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    Discontinued [GID-TA10880]

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued [GID-TA11020]

    Technology appraisal guidance
    Discontinued

  13. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued [GID-TA11244]

    Technology appraisal guidance
    Discontinued

  14. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued [GID-TA10958]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued [GID-TA10583]

    Technology appraisal guidance
    Discontinued